About: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 August 1995

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в серпні 1995 (uk) article scientifique publié en 1995 (fr) im August 1995 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'agostu de 1995 (ast) scientific article published on 01 August 1995 (en)
publication date	wds:Q71940328-8F36C52E-660E-423A-812D-5D984CDBEA05
publication date	1995-08-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q71940328-9C63628B-9594-45A3-A79E-55595D753AFE
language of work or name	English
author name string	wds:Q71940328-9363997A-00C6-4B95-A948-67B7B2E8EE6E wds:Q71940328-B7BA03AE-975C-4340-9EE2-2A9D31EDAE6D wds:Q71940328-C2131512-CA8A-4C83-84EE-5142FE0A8350
author name string	T J Kieffer C H McIntosh R A Pederson
rdfs:label	Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV (en) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV (nl)
skos:prefLabel	Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV (en) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV (nl)
name	Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV (en) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV (nl)
title	wds:Q71940328-63F8CA94-573F-4573-9164-A46EF6F06FB6
title	Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV (en)
page(s)	wds:Q71940328-CE0BF278-04EF-4CAF-B9DA-695CAF8F206F
page(s)	3585-3596
instance of	wds:Q71940328-80FD142F-5DA4-4612-9982-B6F7F4105292
instance of	scholarly article
PubMed ID	wds:Q71940328-74A522E2-E996-46E4-A643-6ECD005944A0
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7628397
PubMed ID	7628397
published in	wds:Q71940328-D6561982-96BE-415C-BE5C-1D39AA3831EE
published in	Endocrinology
issue	wds:Q71940328-0AAD38BF-9E2B-4B67-B521-3EB6A9B688F7
volume	wds:Q71940328-CCB76B68-927F-47CF-9FD1-CAE26BC10AA3
issue	8
volume	136
DOI	wds:Q71940328-E8AEABF3-6EBB-496D-A076-487ED22560CC
DOI	http://dx.doi.org/10.1210/ENDO.136.8.7628397
DOI	10.1210/ENDO.136.8.7628397
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q71940328
is cites work of	Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Gastrointestinal hormones regulating appetite An intrinsic agonist mechanism for activation of glucagon-like peptide-1 receptor by its extracellular domain. Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Incretins, insulin secretion and Type 2 diabetes mellitus Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice Cardiovascular biology of the incretin system Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological increti The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance Enhancing Incretin Action for the Treatment of Type 2 Diabetes Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Sitagliptin exerts an antinflammatory action Therapeutic vaccine against DPP4 improves glucose metabolism in mice Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor Extracellular proteases as targets for drug development Evolution of exenatide as a diabetes therapeutic A VGF-derived peptide attenuates development of type 2 diabetes via enhancement of islet β-cell survival and function. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Targeting proteases: successes, failures and future prospects Dipeptidyl Aminopeptidase IV from Stenotrophomonas maltophilia Exhibits Activity against a Substrate Containing a 4-Hydroxyproline Residue Exendin-4 decreases amphetamine-induced locomotor activity Entry of exendin-4 into brain is rapid but may be limited at high doses Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist The role of gut hormones in glucose homeostasis Glucagon-like peptide 1(GLP-1) in biology and pathology Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus Glucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signaling Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice Ligand binding pocket formed by evolutionarily conserved residues in the glucagon-like peptide-1 (GLP-1) receptor core domain Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor GIP and GLP-1, the two incretin hormones: Similarities and differences Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes. High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. The role of incretins in glucose homeostasis and diabetes treatment Regulation of glucose homeostasis by GLP-1 The cardiovascular effects of GLP-1 receptor agonists Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors Clinical application of glucagon-like Peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists Novel extrapancreatic effects of incretin Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist The expression and function of glucose-dependent insulinotropic polypeptide in the embryonic mouse pancreas Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software